Nwam LLC Acquires 5,476 Shares of Stryker Corporation $SYK

Nwam LLC grew its holdings in Stryker Corporation (NYSE:SYK) by 226.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,892 shares of the medical technology company’s stock after purchasing an additional 5,476 shares during the quarter. Nwam LLC’s holdings in Stryker were worth $2,593,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter valued at about $26,000. Sankala Group LLC acquired a new stake in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the fourth quarter worth about $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker during the fourth quarter worth approximately $28,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.7%

NYSE:SYK opened at $316.46 on Thursday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The stock’s fifty day simple moving average is $311.28 and its 200-day simple moving average is $337.10. The firm has a market capitalization of $121.32 billion, a P/E ratio of 36.63, a P/E/G ratio of 1.99 and a beta of 0.77.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the company posted $2.84 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Ratings Changes

Several analysts have recently commented on SYK shares. Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. BTIG Research set a $371.00 price objective on Stryker in a report on Monday. Weiss Ratings lowered Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Barclays lowered their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Finally, Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $392.52.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.